HCV | WEBCASTS

Beginning Date

06/20/2016

Ending Date

06/20/2017

0.5

credit

Speakers

Fred Poordad, MD
VP, Academic and Clinical Affairs
The Texas Liver Institute
Clinical Professor of Medicine
Chief, Hepatology
UT Health Science Center at San Antonio
San Antonio, Texas

Mark Sulkowski, MD
Medical Director, Viral Hepatitis Center
Professor of Medicine
Johns Hopkins Medical Center
Baltimore, Maryland

Webcast

Webcast must be viewed in its entirety to claim credit.

Accredited by:

This activity is provided by the Chronic Liver Disease Foundation and endorsed by IC-HEP United States.

This activity Supported by:

Bristol-Myers Squibb & Merck & Co.

Target Audience

This educational program will address the educational needs of health care professionals on the screening, diagnosis and management of patients with chronic liver disease.

Educational Objectives

At the conclusion of this activity, participants will be able to:

•	Communicate the prevalence of and risk factors for HIV/HCV coinfection and recognize the effects of coinfection on HCV disease progression
•	Discuss the treatment of HCV in this special patient population by reviewing data on direct acting antivirals and explaining special considerations such as drug interactions

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and the Chronic Liver Disease Foundation (CLDF). The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest:

All faculty and staff involved in the planning or presentation of continuing education activities sponsored/provided by the Annenberg Center for Health Sciences at Eisenhower (ACHS) are required to disclose to the audience any real or apparent commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. John Bayliss, VP, Business Development, spouse is an employee of Amgen, Inc.; all other staff at the Annenberg Center for Health Sciences at Eisenhower and the Chronic Liver Disease Foundation (CLDF), have no relationships to disclose.

The opinions expressed during the live activity are those of the faculty and do not necessarily represent the views of the Annenberg Center for Health Sciences at Eisenhower. The information is presented for the purpose of advancing the attendees' professional development.

Learner Assurance Statement

The Annenberg Center for Health Sciences at Eisenhower is committed to resolving all conflicts of interest issues that could arise as a result of prospective faculty members' significant relationships with drug or device manufacturer(s). The Annenberg Center for Health Sciences at Eisenhower is committed to retaining only those speakers with financial interests that can be reconciled with the goals and educational integrity of the CME activity.

Additional Planners/Reviewers affiliation and disclosure statements

Fred Poordad, MD:
Grant/Research support: Abbvie, Achillion Pharmaceuticals, Anadys Pharmaceuticals, Biolex Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Gilead Sciences, GlaxoSmithKline, GlobeImmune, Idenix Pharmaceuticals, Idera Pharmaceuticals, Intercept Pharmaceuticals, Janssen, Medarex, Medtronic, Merck, Novartis, Santaris Pharmaceuticals, Scynexis Pharmaceuticals, Vertex Pharmaceuticals, ZymoGenetics
Speaker: Gilead, Kadmon, Merck, Onyx/Bayer, Genentech, GSK, Salix and Vertex
Consultant/Advisor: Abbvie, Achillion Pharmaceuticals, Anadys Pharmaceuticals, Biolex Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, GlobeImmune, Idenix, Merck, Novartis, Tibotec/Janssen, Theravance and Vertex.

Mark Sulkowski, MD:
Grant/Research Support: AbbVie, Bristol-Myers Squibb, Gilead, Janssen, Merck
Advisory Board: AbbVie, Cocrystal, Bristol-Myers Squibb, Gilead, Janssen, Merck, Trek